Endologix (NASDAQ:ELGX) and Calmare Therapeutics (OTCMKTS:CTTC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Endologix and Calmare Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Endologix -41.19% -89.31% -14.08%
Calmare Therapeutics N/A N/A N/A

Institutional and Insider Ownership

74.3% of Endologix shares are owned by institutional investors. Comparatively, 0.5% of Calmare Therapeutics shares are owned by institutional investors. 1.4% of Endologix shares are owned by insiders. Comparatively, 17.5% of Calmare Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Endologix and Calmare Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Endologix $181.16 million 0.31 -$66.40 million ($0.48) -1.13
Calmare Therapeutics $1.11 million 1.25 -$3.82 million N/A N/A

Calmare Therapeutics has lower revenue, but higher earnings than Endologix.

Analyst Recommendations

This is a summary of current ratings and target prices for Endologix and Calmare Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Endologix 0 4 1 0 2.20
Calmare Therapeutics 0 0 0 0 N/A

Endologix presently has a consensus target price of $3.40, suggesting a potential upside of 529.63%. Given Endologix’s higher probable upside, analysts clearly believe Endologix is more favorable than Calmare Therapeutics.

Volatility and Risk

Endologix has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Calmare Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Summary

Calmare Therapeutics beats Endologix on 7 of the 11 factors compared between the two stocks.

Endologix Company Profile

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions which allows physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Ovation, Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Calmare Therapeutics Company Profile

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.